QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RXRX

QT66Recursion Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
3.23
+0.12+3.86%
OverviewShort InterestFilings
RXRXQT66Recursion Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
3.23+3.86%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.20
Insider Own4.46%
Shs Outstand529.91M
Perf Week2.54%
Market Cap1.39BForward P/E-EPS next Y-0.87Insider Trans-0.26%Shs Float-Perf Month13.33%
Enterprise Value808.67MPEG-EPS next Q-0.25Inst Own-Short Float-Perf Quarter-4.15%
Income-472999491.00P/S20.98EPS this Y23.06%Inst Trans-Short Ratio-Perf Half Y-23.10%
Sales66.29MP/B1.61EPS next Y5.29%ROA-41.79%Short Interest-Perf YTD-21.03%
Book/sh1.93P/C-EPS next 5Y-ROE-54.32%52W High7.18 -55.01%Perf Year-33.26%
Cash/sh1.23P/FCF-EPS past 3/5Y-ROIC-47.11%52W Low2.77 16.61%Perf 3Y-
Dividend Est.-EV/EBITDA-1.69Sales past 3/5Y23.31% 90.37%Gross Margin-34.44%Volatility4.58% 5.73%Perf 5Y-
Dividend TTM-EV/Sales12.20EPS Y/Y TTM28.99%Oper. Margin-882.92%ATR (14)0.25Perf 10Y-
Dividend Ex-Date-Quick Ratio5.47Sales Y/Y TTM11.86%Profit Margin-844.46%RSI (14)48.90Recom2.60
Dividend Gr. 3/5Y-Current Ratio5.47EPS Q/Q56.00%SMA20-2.08%Beta2.96Target Price5.50
Payout0.00%Debt/Eq0.07Sales Q/Q-60.00%SMA50-3.13%Rel Volume1.50Prev Close3.11
Employees800LT Debt/Eq0.05EarningsAug 04SMA200-22.22%Avg Volume16.49MPrice3.23
IPO DateApr 16, 2021Option/ShortYes / YesEPS/Sales Surpr.26.67% -62.50%Net Debt/EBITDA1.21Volume24,733,340Change3.86%
Analyst Ratings
DateActionAnalystRatingTarget
May-14-26ReiteratedMorgan StanleyEqual Weight$11 → $5.50
Dec-17-25ReiteratedUBS$11
Dec-17-25ReiteratedMorgan StanleyEqual Weight$11
Dec-17-25UpgradeJP MorganNeutral → Overweight
Feb-28-25ReiteratedLeerink PartnersMarket Perform$6.00
Sep-04-24ReiteratedNeedhamBuy$11
Sep-03-24ReiteratedKeyBancOverweight$16 → $12
Sep-03-24ReiteratedJefferiesHold$6.00
Jun-26-24ReiteratedKeyBancOverweight$16
Apr-18-22DowngradeB of A SecuritiesBuy → Neutral
Latest News
Jun-17-26
Jun-17-2606:33AM
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its CashSeekingAlpha
Jun-12-26
Jun-12-2612:43PM
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not GuaranteedSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue667559
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A8912145
Gross Profit-22-4614
Selling, General and Administrative Excl. Other158177178
Research and Development421425314
Other Operating Expense-1701
Operating Income-585-648-479
Interest Expense122
Unusual Expense
———
Non-Operating Income (Expense)-22-5-16
Net Income Before Taxes-564-645-465
Income Taxes-50-1
Consolidated Net Income-560-645-464
Net Income From Continuing Operations-560-645-464
Net Income-560-645-464
EPS (Recurring)-1.20-1.44-1.69
EPS (Basic, Before Extraordinaries)-1.20-1.44-1.69
EPS (Diluted)-1.20-1.44-1.69
EBITDA-480-559-427
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio25.8924.38—
Gross Margin-33.33-61.3323.73
Operating Margin-886.36-864.00-811.86
Net Margin-848.48-860.00-786.44
Shares Outstanding529447274
Market Capitalization1,7091,828—
Operating Lease Expense
———
Insider Trading Volume
$3.48$3.05$2.63$2.20$1.77● Close Price0.00M0.86M1.71M2.57M3.42MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Gibson ChristopherDirectorJun 05 '26Sale3.6240,000144,800883,735Jun 05 12:00 AM
Khan NajatCEO and PresidentJun 05 '26Sale3.5823,58884,4592,175,796Jun 05 12:00 AM
Bumpus NamandjeDirectorJun 03 '26Sale3.544,38615,52643,171Jun 04 12:00 AM
Borgeson BlakeDirectorJun 02 '26Sale3.6830,000110,4006,169,863Jun 04 12:00 AM
Gibson ChristopherDirectorMay 22 '26Sale3.0840,000123,200883,735May 27 12:00 AM
Gibson ChristopherDirectorMay 07 '26Sale3.3740,000134,800926,556May 08 12:00 AM
Borgeson BlakeDirectorMay 05 '26Sale3.5230,000105,6006,199,863May 07 12:00 AM
Gibson ChristopherDirectorApr 22 '26Sale3.6140,000144,400906,556Apr 24 12:00 AM
Gibson ChristopherDirectorApr 07 '26Sale3.1040,000124,000906,556Apr 08 12:00 AM
Borgeson BlakeDirectorApr 07 '26Sale3.1030,00093,0006,229,863Apr 08 12:00 AM
Gibson ChristopherDirectorMar 23 '26Sale3.2540,000130,000906,556Mar 25 12:00 AM
Taylor Ben RChief Financial OfficerMar 17 '26Sale3.397,95626,9711,180,318Mar 18 12:00 AM
Khan NajatCEO and PresidentMar 09 '26Sale3.3528,29894,6602,262,085Mar 11 12:00 AM
Borgeson BlakeDirectorMar 03 '26Sale3.46170,000588,2006,259,863Mar 04 12:00 AM
Gibson ChristopherDirectorFeb 19 '26Sale3.4640,000138,400906,556Feb 19 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR